
ESOCAP FEATURED IN *THE MEDICINE MAKER*

Basel, Switzerland, February 2, 2022

“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said Isabelle Racamier, EsoCap AG CEO. “The interview is a great opportunity to highlight the challenges of esophageal disease and how EsoCap is innovating localized esophagus treatment”.

About The Medicine Maker

The development of new drugs and biological medicines draws on the talent, passion and experience of a wide range of professionals. The goal of The Medicine Maker is to integrate all aspects of the process, from registration of an Investigational New Drug (IND) or Biologics License Application (BLA) through to the market launch of new therapies, and beyond. The Medicine Maker combines topical news coverage with practical, pragmatic articles that are meaningful to the daily working life of experts in the clinical, regulatory, development and manufacturing fields. Feature articles tell the stories behind the biggest concepts, issues and advances in the field, and departments will cover topics in business, policy to advice and career development. The Medicine Maker launched in September 2014, and is available in a multitude of formats.

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a

unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach with the current standard of care. The lead candidate ESO-101 has received Orphan Drug Designation from the FDA in the treatment of EoE and is in clinical development.

EsoCap owns and develops a unique drug delivery platform, allowing the efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract. With a strong IP position, EsoCap technology is widely protected.

For more information, please visit www.esocapbiotech.com and follow EsoCap on [LinkedIn](#) and [Twitter](#).

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com

